Literature DB >> 9514073

Antiproliferative action of pyrrolobenzoxazepine derivatives in cultured cells: absence of correlation with binding to the peripheral-type benzodiazepine binding site.

D M Zisterer1, N Hance, G Campiani, A Garofalo, V Nacci, D C Williams.   

Abstract

Three novel peripheral-type benzodiazepine binding site (PBBS) ligands, NF 182, 213 and 262, along with the classically used PBBS ligands, PK 11195 and Ro5-4864, were found to inhibit, at micromolar concentrations and in dose-dependent manner, the proliferation of rat C6 glioma and human 1321N1 astrocytoma, without being cytotoxic. This antiproliferative effect is mediated by arrest in the G1 phase of the cell cycle and does not appear to be mediated by a specific interaction of these ligands with the peripheral-type benzodiazepine binding site.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9514073     DOI: 10.1016/s0006-2952(97)00500-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

1.  Oxidative stress induces apoptosis in C6 glioma cells: involvement of mitogen-activated protein kinases and nuclear factor kappa B.

Authors:  M Marangolo; M M McGee; K F Tipton; D C Williams; D M Zisterer
Journal:  Neurotox Res       Date:  2001-08       Impact factor: 3.911

2.  Bcl-2 resistant mitochondrial toxicity mediated by the isoquinoline carboxamide PK11195 involves de novo generation of reactive oxygen species.

Authors:  D A Fennell; M Corbo; A Pallaska; F E Cotter
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

Review 3.  Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepines.

Authors:  L M Greene; S Butini; G Campiani; D C Williams; D M Zisterer
Journal:  J Cancer       Date:  2016-12-04       Impact factor: 4.207

4.  Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination.

Authors:  Renee Sokias; Eryn L Werry; Sook W Chua; Tristan A Reekie; Lenka Munoz; Erick C N Wong; Lars M Ittner; Michael Kassiou
Journal:  Medchemcomm       Date:  2016-11-15       Impact factor: 3.597

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.